BioLineRx Ltd. (TLV: BLRX)
Israel
· Delayed Price · Currency is ILS · Price in ILA12.40
0.00 (0.00%)
Nov 17, 2024, 3:49 PM IDT
BioLineRx Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 17.05 | 4.8 | - | - | - | - | Upgrade
|
| Cost of Revenue | 6.04 | 3.69 | - | - | - | - | Upgrade
|
| Gross Profit | 11 | 1.11 | - | - | - | - | Upgrade
|
| Selling, General & Admin | 35.27 | 31.58 | 11.53 | 5.31 | 4.75 | 4.67 | Upgrade
|
| Research & Development | 10.55 | 12.52 | 17.63 | 19.47 | 18.17 | 23.44 | Upgrade
|
| Operating Expenses | 45.82 | 44.1 | 29.16 | 24.78 | 22.93 | 28.11 | Upgrade
|
| Operating Income | -34.82 | -42.99 | -29.16 | -24.78 | -22.93 | -28.11 | Upgrade
|
| Interest Expense | -2.89 | -2.14 | -1.79 | -0.98 | -1.47 | -2.25 | Upgrade
|
| Interest & Investment Income | 2.13 | 2.01 | 0.69 | 0.28 | 0.24 | 0.78 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.06 | 0.06 | -0.35 | 0.28 | -0.14 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 12.1 | -10.84 | 5.64 | -1.85 | -5.72 | 4.14 | Upgrade
|
| EBT Excluding Unusual Items | -23.42 | -53.91 | -24.95 | -27.05 | -30.02 | -25.45 | Upgrade
|
| Asset Writedown | -6.7 | -6.7 | - | - | - | - | Upgrade
|
| Pretax Income | -30.12 | -60.61 | -24.95 | -27.05 | -30.02 | -25.45 | Upgrade
|
| Net Income | -30.12 | -60.61 | -24.95 | -27.05 | -30.02 | -25.45 | Upgrade
|
| Net Income to Common | -30.12 | -60.61 | -24.95 | -27.05 | -30.02 | -25.45 | Upgrade
|
| Shares Outstanding (Basic) | 1,073 | 963 | 774 | 663 | 253 | 146 | Upgrade
|
| Shares Outstanding (Diluted) | 1,073 | 963 | 774 | 663 | 253 | 146 | Upgrade
|
| Shares Change (YoY) | 22.24% | 24.47% | 16.75% | 162.19% | 72.70% | 34.82% | Upgrade
|
| EPS (Basic) | -0.03 | -0.06 | -0.03 | -0.04 | -0.12 | -0.17 | Upgrade
|
| EPS (Diluted) | -0.03 | -0.06 | -0.03 | -0.04 | -0.12 | -0.17 | Upgrade
|
| Free Cash Flow | -30.42 | -22.72 | -26.37 | -23.67 | -23.21 | -22.73 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.02 | -0.03 | -0.04 | -0.09 | -0.16 | Upgrade
|
| Gross Margin | 64.55% | 23.08% | - | - | - | - | Upgrade
|
| Operating Margin | -204.22% | -895.65% | - | - | - | - | Upgrade
|
| Profit Margin | -176.67% | -1262.79% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -178.46% | -473.42% | - | - | - | - | Upgrade
|
| EBITDA | -33.08 | -42.17 | -28.5 | -24.07 | -21.99 | -27.17 | Upgrade
|
| D&A For EBITDA | 1.74 | 0.82 | 0.65 | 0.7 | 0.93 | 0.94 | Upgrade
|
| EBIT | -34.82 | -42.99 | -29.16 | -24.78 | -22.93 | -28.11 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.